How to access Keytruda from the UAE, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE patient with a solid tumour for which immunotherapy is indicated, non-small cell lung cancer, melanoma, head and neck cancer, urothelial cancer, triple-negative breast cancer, renal cell carcinoma, certain gastrointestinal cancers, and other FDA-approved settings, may receive a prescription for Keytruda (pembrolizumab) from their treating oncologist. Keytruda is FDA-approved, developed by Merck, and is one of the most widely used anti-PD-1 immunotherapies across oncology. In the UAE, Keytruda is accessible through hospital pharmacies for several indications; for other indications or where supply timing is an issue, the Ministry of Public Health (MoHAP) named-patient import route is available.
This guide explains the legal pathway, what documentation your physician needs, typical timing and how quotes work, and where Reserve Meds fits in.
Ask about Keytruda in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Keytruda is an anti-PD-1 monoclonal antibody given as an intravenous infusion every three or six weeks in an outpatient oncology setting. Eligibility depends on the specific tumour type, line of therapy, and, for many indications, biomarker testing (PD-L1 expression, microsatellite instability / mismatch-repair status, tumour mutational burden, or others depending on FDA labeling). Pivotal studies have demonstrated extended overall and progression-free survival across multiple indications relative to prior standards. Your oncologist will confirm eligibility, biomarker status where applicable, and set up baseline autoimmune screening and on-treatment monitoring.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Keytruda legally importable into the UAE?
Yes, through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework, administered in coordination with the UAE Council for Healthcare Practitioners (QCHP)-licensed physician and the treating hospital pharmacy. The named-patient mechanism allows an Emirati-licensed physician to request import of a medicine not locally registered, or not locally available in the formulation or quantity required, when: (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is suitable, (c) the physician takes clinical responsibility, and (d) chain of custody is documented end to end.
For Keytruda specifically, the infrastructure requirements are modest, an outpatient oncology infusion suite with standard cold-chain storage, and most the UAE tertiary centres already administer anti-PD-1 therapy routinely.
How the pathway works, step by step
- Consultation with your treating oncologist. The decision to prescribe Keytruda is a clinical one, supported by biomarker testing where applicable and a written rationale.
- Infusion facility identification. An oncology day-unit with cold-chain storage is confirmed.
- MoHAP named-patient application. Your physician or the hospital pharmacy files the application with clinical rationale, patient reference, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure product from authorised distribution.
- Cold-chain shipment. The product ships with continuous temperature monitoring and chain-of-custody documentation.
- Arrival and first infusion. The hospital pharmacy releases doses to the oncology day-unit for administration on your cycle schedule.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming tumour type, biomarker status where relevant, line history, and Keytruda as the indicated treatment
- Verification of their UAE medical licence (QCHP)
- Identification of the administering infusion facility
- Patient identifier (QID reference where required)
- Planned dosing schedule (typically 200 mg every three weeks or 400 mg every six weeks, depending on indication)
Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect to see, including the immune-related adverse event surveillance plan that is standard for anti-PD-1 therapy.
Costs and timing
Medicine price: quote on request. You get a written quote for your case before you commit. Cold-chain logistics, MoHAP documentation handling, and coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit. Subsequent cycles ship on a rolling basis against your infusion calendar.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: many the UAE families prefer local continuity of care and are well served by the country's tertiary oncology infrastructure. Named-patient import supplements, rather than replaces, local management; all administration and monitoring is by your the UAE-based oncology team.
Reserve Meds's role
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Keytruda specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoHAP review.
- Logistics. Cold-chain, temperature-monitored shipment coordination.
- Dedicated case lead. A named point of contact for your family and your physician through intake and cycle-to-cycle refills.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist and the administering infusion facility.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP named-patient framework with appropriate documentation. Cross-border named-patient import is a routine mechanism across the UAE oncology. See our trust and compliance page.
My tumour isn't one of the classic Keytruda indications, can it still be prescribed? Keytruda's FDA label covers many tumour types, plus a tissue-agnostic indication for mismatch-repair-deficient / MSI-high tumours. Your oncologist will review FDA labeling and determine whether your specific tumour and biomarker profile meet an approved indication.
What are immune-related adverse events? Anti-PD-1 therapy can produce autoimmune inflammation in various organs (thyroid, colon, liver, lung, skin, others). These are recognised, and management protocols are well established. Your oncology team will brief you.
Can I switch between three-weekly and six-weekly dosing? FDA labeling supports both schedules for several indications at the oncologist's discretion. Your doctor will choose the schedule that fits your care plan.
Will insurance cover this? Cash-pay is the default for named-patient supply. Some UAE private insurers consider reimbursement case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step
For Keytruda coordination in the UAE, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
Frequently asked questions
How can I get Keytruda in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Keytruda for patients in the UAE through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Keytruda in the UAE through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Keytruda. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Keytruda in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Keytruda to a patient in the UAE?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Keytruda to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Keytruda in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Keytruda in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.